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Abstract: The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor
4 (CXCR4), and both proteins play a central role in the modulation of diverse cellular processes,
including proliferation and cell survival. While in chronic myeloid leukemia (CML) the CXCR4
is downregulated, thereby promoting the mobilization of progenitor cells into blood, the receptor
is highly expressed in breast cancer cells, favoring the migratory capacity of these cells. Recently,
the LIM and SH3 domain protein 1 (LASP1) has been described as a novel CXCR4 binding partner
and as a promoter of the PI3K/AKT pathway. In this study, we uncovered a direct binding of
LASP1, phosphorylated at S146, to both CXCR4 and AKT1, as shown by immunoprecipitation assays,
pull-down experiments, and immunohistochemistry data. In contrast, phosphorylation of LASP1
at Y171 abrogated these interactions, suggesting that both LASP1 phospho-forms interact. Finally,
findings demonstrating different phosphorylation patterns of LASP1 in breast cancer and chronic
myeloid leukemia may have implications for CXCR4 function and tyrosine kinase inhibitor treatment.
Keywords: LASP1; CXCR4; AKT1; CML; breast cancer
1. Introduction
The LIM and SH3 protein 1 (LASP1) was first identified in human metastatic lymph nodes in
breast cancer patients [1]. The LASP1 gene is located on chromosome 17q12 and encodes for a protein
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with an N-terminal LIM domain, followed by two nebulin-like repeats, a linker region with two
phosphorylation sites at S146 and Y171, and a C-terminal SH3 domain, known to bind to proline-rich
proteins like lipoma-preferred partner (LPP), zyxin, dynamin, vimentin, and zona occludens protein
2 (ZO2) [2]. Phosphorylation of LASP1 at S146 by protein kinase A or protein kinase G mainly
attenuates binding to filamentous F-actin, zyxin, and lipoma protein partner (LPP), thus allowing
subcellular relocalization of LASP1, [3] while phosphorylation at Y171 by c-Src and c-ABL non-receptor
tyrosine kinases is associated with cell spreading [4] and apoptosis [5]. For the cysteine-rich LIM
domain of LASP1, binding to the chemokine receptors 1-4 (CXCR1-4) at their carboxy-termini has been
described [6]. While the interaction with CXCR1-3 is independent of LASP1 phosphorylation, binding
to CXCR4 requires LASP1 phosphorylation at S146 [6]. CXCR4 is mainly known for its crucial role in
the homing and retention of hematopoietic stem and progenitor cells in stem cell niches of the bone
marrow [7]. In chronic myeloid leukemia (CML), CXCR4 expression is down-regulated by the fusion
protein BCR-ABL, and associated with a defective adhesion of CML cells to bone marrow stroma [8].
In this regard, LASP1 has been identified as member of a six genes signature highly predictive for
CML [9] and a role of LASP1-CXCR4 in CML progression is discussed [10]. In addition, the constitutively
active tyrosine kinase leads to hyperphosphorylation of proteins like Crk-like protein (CRKL) and
LASP1 [11].
Although LASP1 was originally identified as a structural cytoskeletal and adaptor protein [12],
an overexpression of LASP1 has been reported in numerous tumor entities [13] and recent data have
also provided evidence for its transcriptional activity [14,15].
In breast cancer, CXCR4 promotes metastasis to organs like bone, liver, and lung, sites commonly
affected by metastatic breast cancer, where its ligand, C-X-C motif chemokine 12 (CXCL12), is expressed
in large quantities [16,17]. In addition, activation of CXCR4 in breast cancer cells facilitates nuclear
translocation of LASP1 and an association of the protein with the transcription factor Snail, associated
with epithelial-to-mesenchymal transition (EMT), and the protein complex UHRF1-DNMT1-G9a,
involved in epigenetic modulation, is observed [14].
CXCR4 mediates intracellular signaling through a classical heterotrimeric G-protein, composed of
Gαi, Gβ, and Gγ subunits. The Gαi monomer inhibits adenylyl cyclase activity and triggers MAPK
and PI3K pathway activation [18], whereas the Gβγ dimer induces intracellular calcium mobilization
through the activation of phospholipase C. Recent evidence also points towards an influence of
LASP1 on the PI3K/AKT pathway, one of the most frequently dysregulated signals in cancer [19].
This pathway is initiated by receptor tyrosine kinase (RTK) or G-protein coupled receptor activation,
like CXCR4, thus inducing phosphorylation of PIP2 to PIP3 by PI3K, thereby recruiting AKT1 and
phosphoinositide-dependent kinase (PDK1) to the plasma membrane, where AKT1 is phosphorylated
by PDK1 at T308. Full activation requires additional AKT1 phosphorylation at S473 by the mTOR2
complex. The process is negatively regulated by phosphatases, either by direct dephosphorylation of
AKT1, or by PTEN (phosphatase and tensin homolog) converting PIP3 back to PIP2 [20].
Decreased pAKT1-S473 phosphorylation after LASP1 depletion has been observed before in
several tumor cell lines, glioblastoma [21], gall bladder [22] and nasopharyngeal carcinoma [23], while
LASP1 overexpression induces phosphorylation in colorectal cancer cells [24] and non-small cell
lung cancer [25]. However, the underlying mechanisms are still controversial. Shao et al. suggested
a molecular mechanism by which LASP1 and COPS5 (COP9 signalosome subunit 5) synergistically
stimulate ubiquitination and degradation of 14-3-3, indirectly causing AKT1-S473 phosphorylation [24].
A recent publication by the same group proposed that LASP1 promotes ubiquitination and degradation
of PTEN, thus enhancing PIP2 phosphorylation to PIP3 and a concomitant AKT activation [23].
In this study, we demonstrate a direct interaction of LASP1 with AKT1. In addition, we investigate
the differences in LASP1-CXCR4 signaling in breast cancer and CML, as these two tumor entities
display different roles for CXCR4, despite comparable overexpression of the receptor binding-partner
LASP1. The results prompted us to propose two connected models, explaining the variations in
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tumor progression in solid breast cancer and hematopoietic malignancy based on differences in
LASP1 phosphorylation.
2. Materials and Methods
2.1. Plasmid Constructs and Mutagenesis
pcDNA3-HA-AKT1 full length (Addgene, Cambridge, MA, USA, plasmid #73408) and
pCDNA3-HA-AKT1-aa1-408 (Addgene, plasmid #73412) were a gift from Chen [26]. Point mutations
within AKT1 sequence (L420S, L426S, and R465S) were performed using the Agilent QuickChange XL
Site-directed mutagenesis kit (Agilent, Santa Clara, CA, USA).
Generation of MDAMB-231 stably transfected with shRNA LASP1 was described earlier [15].
Full-length cDNA for human LASP1 (GenBank accession number X82456) was cloned into the
pGEX4T1 vector (GE Healthcare, Freiburg, Germany). For the generation of the LASP1-∆LIM (aa
64–261) and LASP1-∆SH3 (aa 1–190) deletion mutants, we used the internal Ncol and Pst1 restriction
sites in the human LASP1 cDNA, respectively. The fragments were recloned into pGEX4T1 [27].
Full-length cDNA of human LASP1 [28] was cloned into Venus-pcDNA3 (a kind gift from A.
Miyawaki [29]) using the BamH1/EcoRI restriction sites.
The 3HA-tagged CXCR4 in pcDEF3 was kindly provided by M.J. Smit (Vrije University, Amsterdam,
The Netherlands) and was used to create the 3HA-CXCR4-CFP construct by fusing enhanced cyan
fluorescence protein (eCFP; BD Bioscience Clontech, Heidelberg, Germany) in-frame to the C-terminal
end of the receptor following S352. The effusion was done by the standard PCR extension overlap
technique, thereby deleting the C-terminal stop-codon of the receptor and the initial methionine codon
of the fluorescent protein.
Recombinant human CXCL12 (Peprotech, 300-28A, Rocky Hill, NJ, USA) was maintained in
imaging buffer supplemented with 0.1% BSA. All mutants were verified by sequencing.
2.2. Cell Culture and Transfection
The human breast cancer cell lines MDAMB-231, BT-20 (triple-negative breast cancer metastasis),
and MCF-7 (luminal breast cancer), as well as the chronic myeloid leukemia cell lines K562 and
LAMA-84, were purchased from ATCC (Manassas, VA, USA) and grown in RPMI 1640-GlutaMAX™
(Gibco BRL, Wiesbaden, Germany). Human embryonic kidney 293 (HEK-293) cell line was purchased
from ATCC (Manassas, VA, USA) and cultured in DMEM high glucose (Gibco BRL). All media were
supplemented with 10% FBS (Gibco BRL) and Penicillin/Streptomycin (PAA Laboratories, Coelbe,
Germany). All cells were cultivated in a 5% CO2 atmosphere at 37 ◦C in a fully humidified incubator.
The MDAMB-231 cell line, stably transfected with LASP1 specific shRNA, was generated
earlier [3], while BT-20 and MCF-7 breast cancer cells were transfected with LASP1 specific siRNAs,
as described before [30]. Knockout of LASP1 in K562 cells was performed before by CRISPR/Cas9 [10].
HEK-293 cells were transfected with empty pcDNA3 as a control or pcDNA3 containing the cDNA for
human HA-AKT1 (AKT1-WT), HA-AKT1-aa1-408 (AKT1-∆C), HA-AKT1-L420S, HA-AKT1-L425S,
or HA-AKT1-R465S using 0.2 µg/mL DNA and 3 µL/mL FuGENE® HD for 24 h following the
manufacturer’s instructions (Promega, Mannheim, Germany).
Cells were lysed in RIPA+-buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% sodium-deoxycholate,
1% Triton-X-100, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM sodium-pyrophosphate, 10 mM EDTA,
and protease inhibitor mixture). Western immunoblot analysis was performed to assess equal expression.
2.3. Western Blot
Protein lysates were subjected to 10% SDS-PAGE and blotted onto nitrocellulose membrane (GE
Healthcare, Freiburg, Germany). Equal amounts of cells (1× 104) were analyzed by immunoblotting with
the following antibodies: LASP1 [28] (diluted 1:2000); anti-β-Actin (1:3000, #1616, Santa Cruz, Dallas,
CA, USA); pLASP1-S146 (1:700, IgG-1445, Immunoglobe, Himmelstadt, Germany); pLASP1-Y171 (1:500,
Cells 2020, 9, 444 4 of 19
IgG-1418, Immunoglobe); AKT1 (1:100, SAB 4500802, Sigma-Aldrich, Darmstadt, Germany); pAKT-S473
(1:1000, #9271, Cell Signaling, Danvers, MA, USA); pAKT-T308 (1:1000, #9275, Cell Signaling), pERK
1:500, #9102, Cell Signaling), HA-tag (1:700, sc-7392, Santa Cruz, Dallas, TX, USA).
Before overnight incubation at 4 ◦C with primary antibodies, membranes were blocked with
3% dry milk (Biorad, Munich, Germany) in TBS-T (Tris-buffered saline containing 0.1% Tween 20)
for 1 h at room temperature. Immunoblots were probed 1 h with a secondary goat-anti-rabbit or
goat-anti-mouse horseradish peroxidase conjugated antibody purchased from Biorad (1:5000) and
developed by using the enhanced chemiluminescence reagent (GE Healthcare, Freiburg, Germany).
Chemiluminescence images were taken using the Amersham Imager 600(GE Healthcare, Freiburg,
Germany) and quantified by the Image QuantTL software (GE Healthcare, Freiburg, Germany).
2.4. Generation of GST-LASP1, His-LASP1 and GST-CRKL
The generation and purification of GST-LASP1 [3], His-LASP1 [15], and GST-CRKL [11] labeled
proteins has been described in detail earlier.
2.5. GST-LASP1 Phosphorylation
A total of 5 µg GST-LASP1 was phosphorylated for 30 min by 0.5 µg recombinant active Lyn kinase
(Sigma-Aldrich) according to the supplier’s recommendations at 30 ◦C in 100 µL phosphorylation
buffer (5 mM Tris, 1 mM MgCl2, 0.1 mM DTT, and 100 µM ATP). PKA phosphorylation was performed
with 0.3 µg purified C-subunit [31] at 30 ◦C in a total volume of 100 µL containing 20 mM Tris/HCl
buffer pH 7.4, 10 mM MgCl2, 5 mM β-mercaptoethanol (Gibco, BRL), 0.01% (w/v) bovine serum
albumin (Figure 1B).
2.6. Immunoprecipitation and Pull-Down
LASP1 immunoprecipitation (IP) in K562 and MDAMB-231 cells was performed by rotation of
2 × 106 cells in 500 µL RIPA+-buffer with 2 µg LASP1 monoclonal B8 antibody (Nanotools, Freiburg,
Germany) for 2 h at 4 ◦C, followed by incubation with A/G sepharose beads (Santa Cruz) for another
2 h at 4 ◦C. After washing the sepharose beads two times with ice-cold PBS, AKT1 binding to LASP1
was analyzed by Western blot.
For LASP1 pull-down, 2 × 106 HEK-293 cells in 500 µL RIPA+-buffer (substituted with 160 nM
nilotinib to inhibit BCR-ABL activity and His-LASP1 tyrosine phosphorylation) were incubated with
20 µg His-tagged LASP1 for 2 h at 4 ◦C, followed by incubation with 50 µL Ni-NTA beads (GE
Healthcare, Freiburg, Germany) for 60 min. The immune complex was washed twice with ice-cold PBS
buffer and prepared for SDS-PAGE.
2.7. Generation of Cxcr4−/− Bone Marrow Derived Dendritic Cells
Cxcr4-floxed mice [32], kindly provided by Dr. Zou (Columbia University, New York, NY, USA,
C57Bl/6 background), were crossed with C57Bl/6 CD11c-cre+ mice to obtain CD11c-cre+ Cxcr4+/+ (WT)
and CD11c-cre+ Cxcr4flox/flox mice (Cxcr4−/−) mice. BM-derived dendritic cells were generated from
these, as described previously [33]. Briefly, femurs were removed from donor mice, the bone marrow
was flushed and 1 × 106 cells were cultured in 24-well plates in RPMI-1640 with 2 mM L-Glutamine
(Gibco BRL) containing 10% heat-inactivated fetal calf serum, 100 U/mL penicillin/streptomycin, and
β-mercaptoethanol (50 µM, Gibco BRL) supplemented with 50 ng/mL GM-CSF (Peprotech). Medium
was renewed at days 3 and 5. BMDCs were used at day 7.
2.8. Radioactive Kinase Assay
Constitutive active Lyn kinase and ABL kinase were purchased from Sigma-Aldrich and BPS
Biosciences (San Diego, CA, USA). Assay was performed with 0.01 µM kinase and 0.1 µM substrate
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(His-LASP1 and GST-CRKL) in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA
at 30 ◦C in the presence of 50 µM [32P]-ATP for the times indicated.
2.9. PCR-Primer for Chemokine Receptors
mCXCR4-fwd: 5′-CCATGGAACCGATCAGTGTG
mCXCR4-rev: 5′-TGAAGTAGATGGTGGGCAGG
mCXCR7-fwd: 5′-GAAGCCCTGAGGTCACTTGG
mCXCR7-rev: 5′-CACAGTGTCCACCACAATGC
2.10. Life Cell Imaging
Prior to transfection, HEK-293 cells were seeded on individual 24 mm glass coverslips placed in
wells of a 6-well plate. The coverslips were pre-incubated with ploy-D-lysine for 30 min and washed
once with PBS. After 6 h, the media was replaced with fresh media and the cells were transfected with
500 ng 3HA-CXCR4-CFP and 50 ng of Venus-LASP1 per well using the Effectene transfection reagent
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Cells were used for confocal
imaging 48 h after transfection. For the measurements, coverslips were mounted on an AttofluorTM
holder and kept in 190 µL of imaging buffer (140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
10 mM HEPES; pH 7.3) containing 0.1% BSA. Then, 10 µL of 20 µM CXCL12 were carefully added into
the solution to reach a final ligand concentration of 1 µM. The recording started at the same time as the
ligand was added.
The experiments were performed using a Leica TCS SP8 confocal microscope (Leica, Wetzlar,
Germany). Images were taken using a 63× water objective (numerical aperture, 1.4). CFP was excited
at 442 nm using a diode laser. CFP emission fluorescence intensity was detected from 455 to 510 nm.
The YFP was excited with an argon laser at 514 nm and the emission fluorescence intensity was detected
from 525 to 600 nm. The time series was recorded using sequential excitation, and images were taken
at 3 s intervals for 20 min with a 512 × 512-pixel format, line average 1, frame average 1, and 400 Hz.
2.11. Immunofluorescence
For immunofluorescence microscopy, 3 × 104 K562 cells were fixed by adding 10% formalin into
the culture medium for a final concentration of 5%. After 10 min incubation at 4 ◦C, cells were washed
twice with cold PBS at 1000× g for 2 min at 4 ◦C, followed by centrifugation for 10 min at 140× g at RT
to generate cytospins [11]. MDAMB-231 cells were grown until 70% confluence on glass coverslips
and fixed in 4% (w/v) paraformaldehyde in PBS on ice. Fixed cells were permeabilized with 0.1% (w/v)
Triton X-100 in PBS and stained with monoclonal AKT1-Alexa Fluor 488 (Merck, Darmstadt, Germany
#16-293, 1:100 dilution) and affinity-purified polyclonal pLASP1-S146 PE-labelled antibody (diluted
1 µg/mL), as well as CXCR4-Alexa Fluor-488 antibody (Abcam #208128, diluted 1:250). PE-labeling
of rabbit polyclonal pLASP1-S146 was performed with the Abcam R-Phycoerythrin conjugation kit
(#102918, Abcam, Cambridge, UK), following the manufacturer’s instruction. Omnifocal analysis was
done with a Biorevo BZ-9000 (Keyence, Neuisenburg, Germany).
2.12. SH3 Domain Mapping
The 3D protein structure of the LASP1-SH3 domain was designed using PyMOL Molecular
Graphics System, Version 2.0.4 (Schrödinger, LLC, New York, NY, USA) open-source software.
2.13. Statistics
Paired two-tailed Student’s t-test for dependent groups was applied to determine the effects of
LASP1 knockdown on AKT1-S473 phosphorylation. Results were considered significant at p < 0.05
(* p < 0.05; ** p < 0.01; *** p < 0.001; n.s. not significant).
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3. Results
3.1. LASP1 Depletion Negatively Regulates AKT1-S473 Phosphorylation
To confirm previous observations of the effect of LASP1 knockdown on AKT1
phosphorylation [22,24,34], we performed experiments with MDAMB-231 and MCF-7 breast cancer
cells, stably transfected with doxycycline-inducible LASP1-specific shRNA, transiently transfected with
different LASP1-specific siRNAs. After two days in cell culture, cells were tested for LASP1 depletion
and AKT1-S473, AKT1-T308, and ERK phosphorylation by immunoblotting (Figure 1A). Data revealed
a significant reduction in S473 phosphorylation (Figure 1B) after LASP1 depletion in both cell lines,
whereas T308 and ERK1/2 phosphorylation were not affected (Figure 1A). The antibiotic doxycycline
itself had no effects on AKT1 phosphorylatiosr results were obtained with different LASP1-depleted
K562 single clone cell lines (Figure 1).
Figure 1. LASP1 regulates AKT1-S473 phosphorylation. (A) Representative Western blots analyzing
LASP1, pERK, AKT1, pAKT1-T308 and pAKT1-S473 after LASP1 knockdown in MDAMB-231 (stably
transfected with shRNA-LASP1 or nonsense shRNA and downregulated by inducible doxycyclin
treatment (depicted with (+) and (−))), in MCF-7 breast cancer cells (transiently transfected with
different LASP1 specific siRNA), and in LASP1-knockout K562 single cell lines. (B) Impaired AKT1-S473
phosphorylation after LASP1 depletion. Statistical differences were analyzed using the paired t-test
(n = 6).
3.2. LASP1-AKT1 Interaction in MDAMB-231 Breast Cancer Cells
Based on the previous data showing a LASP1-mediated PI3K/AKT1 activation [22,24,34] and our
own findings demonstrating overexpression of LASP1 in breast cancer cells [35] and in CML [11],
we wanted to address whether there is a direct regulation of AKT1 by LASP1 in these cells. We therefore
performed an immunoprecipitation assay with monoclonal LASP1 antibody and indeed could detect
an LASP1-AKT1 interaction in MDAMB-231 breast cancer cells but not in K562 cells. However, when
performing a pulldown assay with His-LASP1 in K562 cell lysates, AKT1 binding to LASP1 was also
detectable (Figure 2A).
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Figure 2. LASP1-AKT1 interaction. (A) Western blot analysis of AKT1 pulled-down by His-LASP1
from K562 cell lysate (left panel), or immunoprecipitated with LASP1 monoclonal B8 antibody from
K562 (middle panel) or MDAMB-231 cell lysate (right panel). AKT1 immunoprecipitation is only seen
in MDAMB-231 lysate. Ponceau staining revealed equal protein input. Experiments were repeated
three times with similar results. (B) Western blot analysis of LASP1, pLASP1-Y171, and pLASP1-S146
in MDAMB-231, MCF-7, K562, and LAMA-84 cells. In chronic myeloid leukemia (CML) cells LASP1
is mainly phosphorylated at Y171, whereas MDAMB-231 and MCF-7 show LASP1 phosphorylation
at Y171 and S146. β-Actin served as loading control. Comparable results were obtained in three
experiments with different passages. (C) Western blot analysis of pulled-down AKT1 using His-LASP1
wild type (WT), LASP1 pre-phosphorylated at Y171 by active Lyn kinase or at S146 by constitutive
active C-subunit of protein kinase A (PKA). AKT1 preferentially binds to pLASP1-S146. The experiment
was repeated three times with equal results. (D) Western blot control of LASP1 pre-phosphorylation by
active Lyn kinase at Y171 or by constitutive active C-subunit of PKA at S146.
To test for differences in LASP1 in MDAMB-231 and K562 cells, we measured the phosphorylation
status of the protein in both cell lines. Interestingly, K562 cells mainly showed LASP1-Y171
phosphorylation, while MDAMB-231 cells demonstrated both phosphorylation at Y171 and S146
(Figure 2B). This difference in phosphorylation pattern was also seen in MCF-7 breast cancer cells and
LAMA-84 CML cells (Figure 2B). When calculating a ratio between pLASP-S146 and pLASP-Y171, data
revealed a 2-3-fold higher Y171 phosphorylation in CML cells compared to breast cancer cells. However,
be aware that the S146 and Y171 phosphorylation intensities do not reflect absolute phosphorylation
due to different antibody specificities.
3.3. AKT1 Preferentially Binds to LASP1 Phosphorylated at S146
These differences in LASP1 phosphorylation prompted us to test LASP1-AKT1 interaction
with respect to different LASP1 phosphorylation states. Pulldown assays were performed with
recombinant His-LASP1, either phosphorylated at S146 by constitutive active C-subunit of PKA,
or at Y171 by active Lyn kinase, and lysates of HEK-293 cells transiently transfected with HA-tagged
full-length AKT1. As depicted in Figure 2C (and Figure 3E), AKT1 bound to unphosphorylated
LASP1, but binding to pLASP1-S146 was increased, whereas phosphorylation at Y171 impaired AKT1
binding. Phosphorylation was controlled by specific antibodies generated against the two LASP1
phosphorylation sites (Figure 2D).
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Figure 3. LASP1-AKT1 interaction (A) Coulombic surface presentation of LASP1-SH3 domain.
Conserved amino acids are depicted as stick models. (B) xPxxPx sequence motifs within the proline-rich
C-terminal regulatory AKT1 domain; negatively-charged amino acids, possibly interacting with the
LASP1-SH3 domain, are marked in red. (C) Western blot input control of AKT1 expression in HEK-231
cells transfected with plasmids harboring AKT1-WT (aa 1–480), AKT1-∆C (aa 1–408), AKT1-K420S,
AKT1-K426S, and AKT1-R465S. GAPDH served as loading control. (D) Western blot analysis of
AKT1 pull-down by GST-LASP1-WT from HEK-231 lysate. Data confirmed an interaction between
LASP1 and the C-terminus of AKT1. (E) Western blot analysis of AKT1 pull-down by GST-LASP1-WT,
GST-pLASP1-Y171, GST-pLASP1-S146, GST-LASP1-∆SH3, and GST-LASP1-∆LIM. Data confirmed
impaired AKT1-∆C binding to LASP1-WT. Ponceau-staining confirmed equal protein input; EV: empty
vector; WT: wild type. All results were confirmed in three independent experiments.
3.4. Interaction between Linker Region of LASP1 and AKT1 C-Terminus
It is known that the SH3 domain modulates a negatively charged cleft by aromatic amino acids,
which interact with proline-rich sequences flanked by positively charged residues (x+) like x+xPxxP
or xPxxPx+ [36]. We used the open source molecular graphic software PyMOL™ to modulate the
SH3 domain of LASP1. In Figure 3A, the domain is shown in a Coulombic surface presentation.
The conserved aromatic amino acids are depicted as stick models. Concurrently, we identified two
putative ligand sequence PxxP motifs with dedicated proline-flanking, negatively-charged amino acids
as consensus target site for SH3 binding at the C-terminus of AKT1, near the S473 phosphorylation site.
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To assess a possible interaction of the LASP1-SH3 domain with the C-terminus of AKT1, we mutated
K420, K426, and R465 (marked in red, Figure 3B) of the full-length AKT (AKT1-WT) to serine. In addition,
we tested truncated AKT1-∆C (aa 1–418) and deletion mutants of LASP1-∆SH3 (aa 1–190) and -∆LIM
(aa 64–261) to map the defined binding region on LASP1 to AKT1. HEK-293 cells were used as an
exogenous system because of high transfection efficiency.
Pulldown experiments with GST-LASP1-WT and endogenous AKT1-WT as well as AKT1-∆C
confirmed the suggested interaction between LASP1 and the C-terminus of AKT1, as truncated AKT1
failed to bind to LASP1 (Figure 3C,D). Unexpectedly, LASP1-∆SH3 showed no reduction in binding to
AKT1-WT (Figure 3E). These data were further confirmed by the AKT1-mutants K420S, K426S, and
R465S, as the loss of any of these positively charged amino acids had no negative effect on LASP1
binding (Figure 3D). Binding was also detected between AKT1 and LASP1-∆LIM. By deductive analysis,
the AKT1-C-terminus favors binding to the S146-phosphorylated LASP1 nebulin-linker region.
Immunofluorescence staining of MDAMB-231 cells confirmed the co-localization of LASP1 with
AKT1 at the cell membrane (Figure 4A, white arrows) and around the nucleus (Figure 4A, orange arrow),
most likely at endosomes. In addition, AKT1 expression was verified in the nucleus. A more detailed
analysis using phycoerythrin (PE)-labeled pLASP-S146 antibody showed the pLASP-S146-AKT1
interaction only around the nucleus (Figure 4B, orange arrows) but not along the membrane. In CML
cells, immunofluorescence detected an exclusive cytosolic expression of LASP1, while AKT1 is present
in the cytosol and in the nucleus (Figure 4C). The observed co-localization in the cytosol is most likely
incidental because of the large nuclei and the reduced cytoplasm volume. Staining of CML cells
with PE-labeled pLASP-S146 was negative and affirmed (a) the lack of this LASP1 isoform in CML
(as already observed in Western blots; Figure 2B), and (b) the specificity of the labeled antibody (data
not shown).
Figure 4. Co-localization of LASP1-AKT1 in MDAMB-231 but not in K562 cells. Merged
immunofluorescences of (A) LASP1 (red, Cy3-labeled) and (B) pLASP1-S146 (red, PE-labeled) with
AKT1 (green, 488-labeled) in MDAMB-231 cells revealed co-localization of LASP1 with AKT1 at the
membrane (white arrows), while pLASP1-S146 is preferentially co-localized with AKT1 perinuclear
(orange arrows). DAPI staining visualized the nuclei. Omnifocal images were captured at 60×
magnification. In K562 cells (C), merged immunofluorescences of LASP1 (red, Cy3-labeled) with
AKT1 (green, 488-labeled) showed coincidental cytosolic localization of both proteins. DAPI staining
visualized the nuclei. Omnifocal images were captured at 100×magnification.
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3.5. CXCR4-LASP1 Binding
Binding of LASP1 to the C-terminus of CXCR4 is dependent on LASP1-S146 phosphorylation [6].
Since in CML LASP1 is highly phosphorylated at Y171 (Figure 2B), we wondered how this phosphorylation
influences LASP1 binding to the receptor. We performed co-immunoprecipitation experiments with
phosphorylated His-LASP1 and the recombinant C-terminus of CXCR4 bound to GST. As seen in
Figure 5A, binding to the CXCR4 C-terminus only occurred with pLASP1-S146 but not pLASP1-Y171 or
unphosphorylated LASP1.
Subsequently, we investigated whether phosphorylation of LASP1 at one site may interfere with
phosphorylation at another site. Therefore, purified recombinant GST-LASP1, bound to Sepharose
beads, was first phosphorylated by PKA or Lyn kinase, kinases were then washed off, and beads were
resuspended in new buffer containing the opposing kinase. As shown in Figure 5B, phosphorylation
of LASP1 at one site hinders phosphorylation at the second site. This suggests either conformational
changes by phosphorylation in the protein [37] or a charge repulsion between the kinase and the
additional negative phosphate group, as positive-charged amino acids (PKA) or hydrophobic residues
(Lyn kinase) are required for optimal substrate binding [38].
Figure 5. Binding of LASP1 to chemokine receptor 4 (CXCR4) is dependent on LASP1-S146 phosphorylation.
(A) Western blot analysis of LASP1, pLASP1-Y171, and pLASP1-S146, co-immunoprecipitated with
GST-CXCR4. Data revealed only binding of pLASP1-S146 with CXCR4. (B) GST-LASP1 beads were
pre-phosphorylated by either constitutive active C-subunit of PKA or active Lyn kinase for 30 min, followed
by washing and continuous incubation with the opposing kinase. Data indicate that phosphorylation
of LASP1 at one site hinders phosphorylation at the second site. Experiments were repeated twice with
similar results.
3.6. CXCR4-Induces LASP1 Phosphorylation in Intact Cells
Given the fact that CXCR4 is known to function as an upstream regulator of AKT1, combined
with identification of LASP1 as a phosphorylation-dependent binding partner of CXCR4 and AKT1,
we addressed if there was a “Yin-Yang” balance between serine and tyrosine phosphorylation of LASP1
and whether the above-mentioned in vitro observations were of any relevance in vivo? To investigate
this question we used murine bone marrow-derived dendritic cells (BMDCs), as these cells harbor the
chemokine receptor CXCR4 and share some common signaling pathways with leukemia stem cells [39].
Subsequently, the Cre/loxP system was used to generate control cells with deleted CXCR4. qRT-PCR
analyses confirmed the deletion of CXCR4 in CD11c-cre+ Cxcr4flox/flox compared to CD11c-cre+ Cxcr4+/+
mice (data not shown). After stimulation with the CXCR4 agonist CXCL12, cells were analyzed for
AKT1 and LASP1 phosphorylation by Western blotting.
In a time-resolved analysis, a three-fold AKT1-S473 phosphorylation was observed within
2 min of CXCL12 stimulation, which declined back to basal levels after 10 min in control cells
(Figure 6B, green line). Simultaneously, cells revealed a 50% increase in LASP1 phosphorylation
at Y171 (Figure 6B, red line), and depicted a dephosphorylation at T156 (corresponding to S146 in
human LASP1 [40] and recognized by the pLASP1-S146 antibody due to high sequence homology
Cells 2020, 9, 444 11 of 19
(Supplemental Figure S1)), which reverted back to basal levels within 10 min (Figure 6B, blue
line). In the CXCR4-deficient cells, basal AKT1 phosphorylation levels diminished, and CXCL12
stimulation triggered a reduced pAKT1-S473 phosphorylation compared to controls cells (Figure 6B,
black line). Basal LASP1 phosphorylation was strongly reduced by CXCR4 deficiency, and no LASP1
phosphorylation could be induced by CXCL12 (Figure 6B, grey line), suggesting CXCR4 being a major
signaling receptor for LASP1 activation.
Figure 6. Role of CXCR4 stimulation on LASP1 phosphorylation in mouse dendritic cells.
(A) Representative Western blot analysis of LASP1, pLASP1-Y171, pLASP1-S146, AKT1 and pAKT1-S473
in mouse dendritic cells harboring CXCR4-WT (CD11c-cre+ Cxcr4+/+ mice (wt) or biallelic CXCR4
knockout (CD11c-cre+ Cxcr4flox/flox mice (Cxcr4−/−); confirmed by qRT-PCR, data not shown) after
stimulation with the CXCR4 agonist CXCL12 for the time points indicated. β-Actin served as loading
control. (B) Densitometric quantification of phosphorylation. Data revealed a three-fold increase
in pAKT1-S473 and a 1.5-fold increase in pLASP1-Y171 phosphorylation in WT cells compared to
CXCR4 knockout cells after 2 min CXCL12 stimulation, which declined to basal levels after 10 min.
Simultaneously, LASP1 was dephosphorylated at S146. Comparable results were obtained in four
independent experiments.
It should be noted that we also checked for CXCR7 levels, as CXCL12 can also partially act through
CXCR7 [41]. However, no expression was detected in the cells by qRT-PCR (data not shown).
3.7. LASP1-CXCR4 Co-Localization in Intact Cells by Life Cell Imaging
To further analyze the LASP1-CXCR4 interaction, we attempted to visualize the co-localization
of both proteins in MDAMB-231 cells. However, immunofluorescence staining of CXCR4 failed due
to low receptor expression and unspecific antibody recognition. It should be noted that we tested
four different commercially available CXCR4 antibodies (antikoerper-online, sc-9046, sc-53534, and
abcam UMB2), among which only one showed a positive protein product of the correct molecular
weight (not shown). We therefore generated CXCR4-CFP and Venus-LASP1 and transiently expressed
the constructs in HEK-293 cells. Under basal conditions, a co-localization of both proteins at the
cell membrane was seen (Figure 7, white arrows at 0 min). Additional cytosolic LASP1 expression
was observed. Stimulation of the cells with 1 µM CXCL12 revealed an internalization of the CXCR4
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receptor over 8 min (Figure 7 and Supplementary Videos S1 and S2). In parallel, LASP1 binding to
CXCR4 declined during the first 2–3 min but increased again after 7–8 min, along with the internalized
receptor (Figure 7, orange arrows). Western blot analysis of this experiment monitored increased
AKT1 activation (phosphorylation of AKT1 at S473) in the presence of CXCR4, concomitant with
partial pLASP1-Y171 phosphorylation/pLASP1-S146 dephosphorylation during the first minutes, and
followed by a return to initial phosphorylation levels after 10 min (Figure 8). This paralleled the
phosphorylation–dephosphorylation time-schedule observed before in dendritic cells (Figure 7).
Figure 7. Life cell imaging of CXCR4 and LASP1 internalization after CXCL12 stimulation. HEK-293
cells were co-transfected with CXCR4-CFP and Venus-LASP1 for 48 h followed by 20 min stimulation
with 1 µM CXCL12. A time series with images taken every 3 s was recorded using sequential excitation.
Images representing time points 0 min (basal phosphorylation—LASP1 and CXCR4 are co-localized at
the membrane, white arrows), 2 min (maximal dephosphorylation of pLASP1-S146—internalization of
CXCR4), and 7 min (perinuclear co-localization of CXCR4 and LASP1, orange arrows) is shown. Images
were captured at 63×magnification. The corresponding video is deposited in the Supplementary Material.
3.8. Enhanced pLASP1-S146 in K562 CML Cells during TKI Treatment
To substantiate our observations concerning the phospho-serine/phospho-tyrosine cross-regulation,
we set out to test LASP1 phosphorylation in K562 cells before and after the inhibition of constitutively
active tyrosine kinase BCR-ABL. The phosphorylation status of the adaptor protein CRKL (Figure 9A,
DMSO control) was used to monitor the efficacy of tyrosine kinase inhibitor (TKI) treatment [42]. After
24 h incubation with 60 nM and 120 nM nilotinib, phosphorylation of LASP1 at S146 increased, whereas
CRKL showed a decrease in phosphorylation (Figure 9A). However, high LASP1-Y171 phosphorylation
levels remained unaltered (Figure 9A), possibly due to phosphorylation by other active tyrosine kinases
in leukemia cells that were not inhibited by nilotinib [43]. Only after treatment with the dual ABL/Src
TK inhibitor dasatinib, a partial dephosphorylation of pLASP1-Y171, was observed (Figure 9A);
phosphorylation of CRKL was completely blocked under these conditions, assuming different substrate
specificities for the tyrosine kinases in CML. To verify these observations, we performed radioactive
kinase assays with constitutive active ABL and Lyn kinase and LASP1, CRKL as substrates. Graphic
visualization of the analyzed radioactive gels revealed faster and stronger phosphorylation of LASP1
by Lyn compared to ABL kinase, whereas CRKL seemed to be a much less preferred substrate of
both kinases (Figure 9B). These findings suggest that in CML patients, the preferential substrate
recognition of LASP1 by Lyn kinase could serve as a new read-out in patients with beginning TKI
resistance, given that these patients show higher Lyn kinase activity as a characteristic of emerging
BCR-ABL-independent resistance [44,45].
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Figure 8. Role of CXCR4 stimulation in LASP1 phosphorylation in CXCR4 expressing HEK-293
cells. (A) Representative Western blot analysis of LASP1, pLASP1-Y171, pLASP1-S146, AKT1, and
pAKT-S473 in HEK-293 cells transfected with CXCR4 and stimulation with the CXCR4 agonist CXCL12
for the time points indicated. β-Actin served as loading control. (B) Densitometric quantification
of phosphorylation. Data revealed a two-fold increase in pAKT1-S473 and a two-fold increase in
pLASP-Y171 phosphorylation concomitant with a 50% decrease in LASP1-S146 phosphorylation in
CXCR4 expressing HEK-293 cells compared to CXCR4-deficient HEK-293 cells after 2 min CXCL12
stimulation, which declined to basal levels after 10 min. Comparable results were obtained in two
independent experiments.
Figure 9. Differences in LASP1 phosphorylation in nilotinib and dasatinib treated K562. (A) Western
blot analysis of K562 cells treated with nilotinib or dasatinib for 24 h showed different phosphorylation
and dephosphorylation for LASP1 and CRKL. (B) Radioactive kinase assay demonstrated higher
substrate affinity of Lyn kinase for LASP1 compared to CKRL.
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4. Discussion
AKT1 function is either regulated by direct inhibition/stimulation or by affecting subcellular
localization. Activation mediates downstream responses, including cell survival, growth, proliferation,
cell migration, and angiogenesis [20]. This study as well as several other publications demonstrated that
LASP1 knockdown decreased AKT-S473 phosphorylation [21–24,34]. Concordantly, LASP1 knockdown
inhibited cell migration and proliferation in several tumor entities [2] and an indirect regulation of
AKT1 by LASP1 was suggested. However, the authors had not taken into account the different
phosphorylation statuses of LASP1 when performing immunoprecipitation experiments or pull-down
assays to identify possible LASP1 binding partner. The study by Goa et al. convincingly demonstrated
an increased activation of AKT1, at least in part, by LASP1 targeting PTEN and inactivating PI3K [23].
In the current study, we analyzed the newly identified direct phosphorylation-dependent binding
of LASP1 to AKT1 and CXCR4, two major players in tumor progression. In view of the new results
and in combination with earlier published data, we propose a model that explains the divergent roles
of LASP1 and CXCR4 in solid breast cancer and in CML cells (Figure 10).
Figure 10. Postulated differences in the CXCR4-LASP1-AKT1 signaling between breast cancer and
CML. In solid breast cancer (left panel), PKA is over-expressed and active, leading to phosphorylation
of LASP1 at S146 and binding of the protein to CXCR4. In addition, LASP1 binds to AKT1 and,
as a scaffolding protein, allows correct binding of AKT1 to the membrane (and potentially the
mTORC2 complex) for efficient S473 phosphorylation. A quantity of AKT1-pLASP1-S146 is present
perinuclear. Low levels of AKT1 and LASP1 are also detected in the nucleus to favor transcriptional
activity. Stimulation of CXCR4 by CXCL12 leads to activation of downstream phosphotyrosine kinases
(PTKs) and increases LASP1-Y171 phosphorylation. Simultaneously, released Gαi inhibits the PKA
pathway and LASP1 becomes dephosphorylated at S146, detaches from the receptor tail, and renders
CXCR4 more sensitive for degradation. In CML (right panel), constitutively active tyrosine kinase
BCR-ABL results in predominant pLASP-Y171 phosphorylation, impeded CRKL-LASP1 binding, and
down-regulation/degradation of CXCR4 receptor. No LASP1 is detected in the expanded nucleus. After
inhibition of BCR-ABL by TKI like nilotinib, CXCR4 is restored in the plasma membrane, LASP1-Y171
phosphorylation decreases, while pLASP1-S146 increases and allows binding to and stabilizing of the
chemokine receptor for homing.
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In breast cancer, LASP1 is partially phosphorylated at S146 by PKA [3] or at Y171 by not otherwise
specified phosphotyrosine kinases (PTKs) (Figure 2B). Phosphorylation at S146 enhances binding to
the C-terminus of CXCR4 (Figure 5A), a chemokine receptor overexpressed on malignant cells and
associated with EMT, upregulation of chemokine receptors, and the secretion of cytokines (IL-6, MCP-1,
and GM-CSF), thereby enhancing migration, lymphatic invasion, and metastatic activity [17,46].
The interaction occurs at the LKIL motif (AA 327–330) [6], a region critical for proper receptor
internalization and degradation [47].
Based on our studies, we suggest that binding of pLASP1-S146 at the C-tail of CXCR4 stabilizes
the receptor and sterically hinders the phosphorylation at multiple PKC serine phosphorylation sites
important for receptor internalization, deactivation, and recycling back to the plasma membrane [47].
Upon stimulation by CXCL12, heterotrimeric G-protein is activated. Gαi inhibits adenylyl
cyclase/cAMP/PKA signaling and activates Src family tyrosine kinases, as seen in the transient
dephosphorylation of LASP1 at the PKA-site (S146) and concomitant phosphorylation at Y171
(Figures 6 and 8). Phosphorylation of LASP1 at Y171 by Src and ABL kinase has already been observed
earlier [4,11]. Increased LASP1-Y171 phosphorylation renders the protein less affine to the CXCR4
C-terminus (Figure 5A), hence, the facilitation of serine and tyrosine phosphorylation of the receptor
by repelling/unblocking [47].
Concomitantly, Gβγ release results in the activation of several pathways, i.e., PI3K/AKT [48],
a key player in tumor cell survival and proliferation [19]. The new data presented in this paper now
demonstrate an additional interaction of LASP1 and pLASP1-S146 with the C-terminus of AKT1
(Figure 3E). A straightforward scaffold model predicted the dependence of AKT1 interaction with
LASP1 at the cell membrane, potentially in combination with mTORC2, as AKT1 phosphorylation
at T308 by PDK1 was not affected (Figure 1). Indeed, the presented immunofluorescence staining
demonstrates a co-localization of LASP1 and AKT1 at the cell membrane, as well as an interaction
of pLASP1-S146 and AKT1 around the nucleus (Figure 4). So far, we cannot rule out LASP1-AKT1
co-localization around the nucleus as well. However, as already shown before, only phosphorylation
of LASP1 at S146 reduces protein binding to F-actin and induces translocation from the membrane to
the cytoplasm [28] as well as into the nucleus when bound to the shuttle protein zona occludens 2 [3].
In the nucleus, LASP1 stabilizes Snail, a transcriptional repressor of adherens junction proteins [14], and
enables matrix metalloprotease expression by modulating AP-1 transcriptional activity [15], processes
that are involved in mesenchymal cell formation and tumor cell migration.
In contrast to breast cancer cells and other solid tumors [2], LASP1 is not detected in the nucleus of CML
cells, either in its tyrosine-phosphorylated form or after serine phosphorylation by forskolin-stimulated
PKA activation [11]. Therefore, a direct transcriptional impact of LASP1 in CML is virtually excluded.
In CML, chromosomal translocation results in an oncogenic BCR-ABL gene fusion that encodes
for the constitutively active BCR-ABL fusion protein. As a result, hyper-phosphorylation of proteins is
observed, among them the newly identified BCR-ABL substrate LASP1 [11]. In contrast to MDAMB-231
breast cancer cells, K562 CML cells show almost exclusively pLASP1-Y171 phosphorylation (Figure 2B),
the CXCR4 receptor is down-regulated [8], and no binding or receptor stabilization is expected. Likewise,
the oncogenic AKT1 activity is not attenuated by pLASP1-Y171. As described in the literature, treatment of
CML cells by TKI up-regulates CXCR4, thus promoting cell migration back to bone marrow stroma [8,49],
and therefore results in BCR-ABL inhibition, decreased tyrosine phosphorylation, and restored PKA
activation [50]. This was partially confirmed in our K562-nilotinib experiments, showing decreased
pCRKL-Y207 phosphorylation, concomitant with increased pLASP-S146 phosphorylation (Figure 9A),
enabling binding to and stabilization of CXCR4. In K562 cells, pLASP1-Y171 dephosphorylation occurred
only after dasatinib treatment, as LASP1 is also a preferential substrate for other tyrosine kinases
(Figure 9B). In patients, an impaired LASP1-Y171 phosphorylation was seen under TKI therapy [11], but
unfortunately, serine phosphorylation was not checked in that study. However, a recent publication
showed imatinib-induced vasodilator-stimulated phosphoprotein (VASP) phosphorylation on S157 in
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K562 cells and in CML patients’ bone marrow cells after imatinib treatment [51]. Completive data
revealed a VASP-Y39 phosphorylation in BCR-ABL-positive leukemic cells [52].
In conclusion, we postulate a model for the divergent CXCR4-LASP1-AKT1 signaling in breast
cancer and CML by differences in LASP1 phosphorylation. While pLASP1-S146 may contribute to
CXCR4 stabilization in solid tumors, thereby promoting metastasis, LASP1-Y171 phosphorylation by
BCR-ABL obviously hinders LASP1-CXCR4 binding and renders the chemokine receptor more sensitive
to degradation in leukemic cells, thus favoring mobilization (Figure 10). Therefore, surveillance of
LASP1 phosphorylation status in CML patients may serve as a new read-out in CML patients under
TKI treatment; appropriate studies are underway.
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